Loading
Imugene Limited Stock: price and insider trades · Australia
Imugene Limited: what insiders have been doing
Headquartered in Melbourne, Imugene Limited belongs to the Health Care sector and traces its origins to 2012. Filings by its managers are published through ASX. Between 18 October 2025 and 18 October 2026, 2 insiders published 6 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Compared with its exchange (2,527 companies, median 3 filings), a count of 6 filings is above the norm.
No insider has bought Imugene Limited shares on the open market in the past twelve months.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. This summary is built from ASX disclosures alone and does not predict where the share price will go.
Insider Decl.
6
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Financial data
as of FY 2025FY ended June 2025 · cache
A$0.04
Analyst consensus
3 analysts1.00/5
A$0.24Target A$0.31(+613%)A$0.43
Income statement
EBITDA-A$84.8M
Net income-A$69M0.0% margin
Valuation
PER (forward)-0.7x
P/Book2.0x
Beta2.07
Balance sheet & cash
Market capA$24M
Total debtA$10.7M
Free Cash Flow-A$90M
Debt / Equity70%
Profitability & ownership
ROE-314.0%
ROA-123.5%
% insiders9.3%
% institutions9.5%
Last declaration on 1 October 2026
About Imugene Limited
Imugene Limited is a biopharmaceutical company focused on developing immunotherapeutic treatments for cancer. It is listed on the Australian Securities Exchange under the ticker IMU.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
